Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.43 |
| ▸ | PDE4A | P27815 | 7/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562063 | 0.92 | ADORA2B (0.46) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL16312179 | 0.81 | ADORA2B (0.45) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL10182806 | 0.80 | ADORA2B (0.46) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL562726 | 0.80 | TP53 (0.50) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL562019 | 0.80 | ADORA2B (0.54) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL3913271 | 0.79 | ADORA2B (0.53) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL10184888 | 0.79 | ADORA2B (0.45) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL10184866 | 0.79 | ADORA2B (0.59) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL562813 | 0.78 | ADORA2B (0.56) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL3911706 | 0.78 | ADORA2B (0.51) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703783-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | INCYTE CORPORATION (US) | 2012-02-09 | — | — | US | disclosed |
| US-8039478-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA3 49/4885ADORA2A 12/4885 |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA3 49/4885ADORA2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.